Dublin, November 1, 2022 (GLOBE NEWSWIRE) – The “Crohn’s Disease Treatment Market Outlook – Epidemiology and Pipeline Analysis” report has been added to ResearchAndMarkets.com Show.

Crohn’s disease is an inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammatory bowel disease treatment market can be divided into two types, such as Crohn’s disease and ulcerative colitis. Among these, Crohn’s disease dominates the global market.

According to estimates, the prevalence of Crohn’s disease was highest in the United States, followed by the United Kingdom and China, in 2020. The increasing prevalence of Crohn’s disease has led to the growth of the Crohn’s disease drug market. It is estimated that one million people developed Crohn’s disease in the United States in 2019.

Crohn’s disease treatments: a pipeline scenario

The Crohn’s Disease portfolio contains more than 100 assets in various stages of development. Most of the drugs sponsored by the industry in active clinical development of Crohn’s disease are in Phase II. Interleukin and integrin antibodies dominate the Crohn’s disease drug pipeline.

Crohn’s disease treatments: a clinical trial scenario

The Clinical Trials Collection contains more than 150 trials in various stages of development. Most of the drugs sponsored by the industry in active clinical development of Crohn’s disease are in Phase II. The distribution of clinical trials across phase I to IV indicates that the vast majority of trials for Crohn’s disease were in phase I and intermediate development, with 75–80% of trials in phase I and II and only 16% in phase III and IV. The United States leads a large number of global clinical trials for Crohn’s disease.

Market Drivers:

Approval of biopharmaceuticals: Biological therapies such as tumor necrosis factor (TNF) and anti-interleukin and integrin antibodies are widely used in many inflammatory diseases such as Crohn’s disease (CD). These drugs are generally considered satisfactory in the treatment of patients who are not adequately controlled by steroids and aminosalicylates.

However, some patients may experience a loss of response to these therapies, especially TNF antagonists. With Stelara (ustekinumab) being the last biologic drug approved for Crohn’s disease in 2016, there is a demand for treatments with new MOAs that are less immunogenic than current offerings and many classes of new treatments are looking to enter the industry over the next few years. Biologics such as integrin antagonists and interleukin inhibitors are making their way into the Crohn’s disease market due to the better clinical profile and convenient patient dosages.

Increasing Prevalence of Crohn’s Disease: The studied market has experienced significant growth, which can be associated with the increased prevalence of Crohn’s disease worldwide. According to the estimates, the prevalence of Crohn’s disease patients was 18,30,704 in 8 million in 2020. This number is expected to reach 21,91,344 from 2021 to 2027.

Market trends:

Emergence of microbiome therapies: Microbiome-based therapies with new mechanisms are emerging for the treatment of Crohn’s disease. Major players in the industry are developing new products and spending heavily on research and development, along with major acquisitions and collaborations.

For example, Takeda has entered into a licensing, co-development, and global co-promotion agreement with Enterome SA Enterome, BiomX, Synlogics, 4D Pharma, Vedanta Bioscience, and many others focused on microbiome-based therapies to treat disease. These players adopt both organic and inorganic growth strategies to strengthen their product portfolio.

Successive launch of new therapies: There are already several biopharmaceuticals indicated for the treatment of moderate to severe Crohn’s disease, including the TNFs Humira (adalimumab), Remicade (infliximab), Cimzia (certolizumab pegol) and the integrin antagonist Entyvio (vedolizumab), and Tysabri (Natalizumab), the interleukin (IL) 12 and 23 inhibitors Stelara (ustekinumab) and Skyrizi (Risankizumab-rzaa). Currently, five major companies have approved brand-name drugs in the Crohn’s disease treatment market – Johnson & Johnson (J&J), AbbVie, Takeda, UCB and Biogen.

Competitive Scenario

The Crohn’s disease treatment market is dominated by many generic companies and selective pharmaceutical/biotech companies offering patents/commercial medicines for Crohn’s disease. The US Food and Drug Administration (FDA) approved TNF-Alpha Humira factor (Adalimumab) for the treatment of Crohn’s disease in 2012.

Then, the FDA approved Stelara (ustekinumab) in 2016 and Skyrizi (risankizumab-rzaa) in 2022 to treat Crohn’s disease. Although generic products still capture a large share of the industry, the arrival of biopharmaceuticals and other targeted therapies indicates a paradigm shift in this therapeutic space during the forecast period.

Notable companies providing pharmaceuticals in the Crohn’s disease treatment market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, Gilead Bioscience, Celltrion, RedHill Biopharma, Landos Biopharma, ReiStone Biopharma, Eli Lilly and Company and many more.

main sellers

  • AbbVie Inc (@AbbVie)
  • Johnson & Johnson (J&J)
  • Takeda Pharmaceutical Company Limited (Takeda)
  • Biogen Corporation (Biogene)
  • UCB SA (UCB)

Other notable sellers

  • Boehringer Ingelheim International GmbH (Boehringer)
  • AstraZeneca Plc (AstraZeneca)
  • Bristol-Myers Squibb Company (BMS)
  • RedHill Biopharma Ltd
  • Sell ​​Tryon

Major Mergers and Acquisitions:

  • In March 2022, Pfizer announced the completion of its acquisition of Arena Pharmaceuticals. Under the terms of the agreement, Pfizer has completed its acquisition of all outstanding shares, options and restricted stock units in the Arena.
  • In June 2021, Synlogic announced that it had entered into a research collaboration agreement with Roche to discover a new synthetic bio-drug for the treatment of inflammatory bowel disease (IBD). Under the terms of the deal, Synlogic and Roche will collaborate to develop a synthetic bio-drug that treats a new, undisclosed target in inflammatory bowel disease.
  • In May 2021, Landos Biopharma, Inc and LianBio entered into an exclusive cooperation and licensing agreement to develop and market omilancor and NX-13 in Greater China (Mainland China, Hong Kong, Taiwan and Macao) and select Asian markets. Under the terms of the cooperation, LianBio will obtain exclusive rights to develop and market omilancor and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia and the Philippines.

Milestones

  • In June 2022, AbbVie announced that the US Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) as the first and only interleukin 23 (IL-23) inhibitor for the treatment of adults with moderate to severe active Crohn’s disease. disease (CD). Approval was based on the ADVANCE and MOTIVATE studies designed to evaluate the efficacy and safety of two doses of rezancizumab, 600 mg and 1200 mg, in adults with moderate to severe active Crohn’s disease compared to placebo.
  • In May 2022, AbbVie announced positive results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn’s disease who had an inadequate or intolerant response to conventional or biological therapy. The results showed that more patients treated with either upadacitinib (15 mg or 30 mg once daily) achieved the combined primary endpoints of endoscopic response and clinical remission, as well as the secondary endpoint of endoscopic sedation, at 1 year (week 52) compared to placebo. .
  • In March 2022, Ossium Health, Inc. That the U.S. Food and Drug Administration (FDA) has accepted the Investigative New Drug (IND) application of OSSM-001, a mesenchymal stem cell (MSC) product, for the treatment of perianal refractory. Fistulas in Crohn’s disease patients. Ossium plans to begin patient screening and enrollment in a phase I multicenter clinical trial evaluating OSSM-001 by the end of 2022.

Answer the main questions:
1. What is the size of the global Crohn’s disease treatment market?
2. What is the growth rate of the global Crohn’s disease market?
3. Who are the major players in the Crohn’s Disease Treatment market?
4. What are the growth factors in the global Crohn’s Disease Treatment Market?
5. Which country has the largest global market share in Crohn’s disease treatment?

Main topics covered:

1. Crohn’s disease overview

2. Overview of the epidemiology of Crohn’s disease
2.1. 8 mm: the historical and expected magnitude of the incidence and prevalence of Crohn’s disease
2.2. 8 mm: a comparative analysis of the incidence and prevalence of Crohn’s disease
2.3-8 mm: historical and projected incidence of Crohn’s disease by disease type
2.4 8 mm: historical and projected incidence of Crohn’s disease by type of severity
2.5–8 mm: historical and projected incidence of Crohn’s disease by sex and age
2.6. 8 mm: historical and projected incidence of Crohn’s disease by disease type
2.7. 8 mm: the historical and expected size of the prevalence of Crohn’s disease by type of severity
2.8. 8 mm: historical and projected prevalence of Crohn’s disease by sex and age group
2.9 US: Historical and projected magnitude of the incidence and prevalence of Crohn’s disease
2.10. China: historical and projected magnitude of the incidence and prevalence of Crohn’s disease
2.11. Japan: historical and projected magnitude of the incidence and prevalence of Crohn’s disease
2.12. Germany: historical and projected extent of the incidence and prevalence of Crohn’s disease
2.13. United Kingdom: Historic and projected incidence and prevalence of Crohn’s disease
2.14. France: historical and projected incidence and prevalence of Crohn’s disease
2.15. Italy: historical and projected magnitude of the incidence and prevalence of Crohn’s disease
2.16. Spain: historical and projected magnitude of the incidence and prevalence of Crohn’s disease

3. Crohn’s disease market size overview

4. Overview of Medications Marketed for Crohn’s Disease
4.1 Drugs marketed for Crohn’s disease – an overview
4.2 Drugs Marketed for Crohn’s Disease – Summary

5. Overview of Crohn’s Disease Pipeline Drugs
5.1 Crohn’s disease pipeline drugs – an overview
5.2 Crohn’s disease pipeline drugs – a snapshot
5.3 Overview of Crohn’s Disease Pipeline Drugs – By Disease Type
5.4. Overview of Crohn’s Disease Pipeline Drugs – By Stage of Development
5.5 Overview of Crohn’s Disease Pipeline Drugs and Snapshot – By Route of Administration
5.6 Overview of Crohn’s Disease Pipeline Drugs and Snapshot – By Mechanism of Action
5.7 Overview of Crohn’s Disease Pipeline Drugs and Snapshot – By Molecule Type
5.8 Overview of Crohn’s Disease Pipeline Drugs and Snapshot – By Geography Type

6. Clinical Trials Overview of Crohn’s Disease
6.1 Overview of clinical trials for Crohn’s disease
6.2 Overview of Clinical Trials for Crohn’s Disease – By Employment Status
6.3 Clinical Trial Overview of Crohn’s Disease – By Product Type
6.4. Overview of clinical trials for Crohn’s disease – by route of administration
6.5. Overview of clinical trials for Crohn’s disease – by molecule type
6.6. Overview of clinical trials for Crohn’s disease – by geography type

7. Crohn’s disease market dynamics
7.1 Crohn’s Disease Treatment Market Drivers
7.2 Limitations of the Crohn’s Disease Treatment Market
7.3. Crohn’s disease treatment market trends

8. Competitive landscape of Crohn’s disease
8.1 Crohn’s Disease Competitive Landscape – Marketed Drugs
8.2 Key Company Profiles
8.3 Crohn’s Disease Treatment Market Competitive Scenario
8.4 key company shot
8.5 Competitive Landscape for Crohn’s Disease – Pipeline Drugs
8.6 Key Features of a Startup Company
8.7 Company key shot
8.8 Other Key Company Profiles

9. Miscellaneous Crohn’s disease

10. Appendix

For more information on this report, visit https://www.researchandmarkets.com/r/kujt2f


        

Leave a Reply